OAB-14
/ Shandong Xinhua Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 14, 2025
Study Design in a Phase 2a Registration Trial for OAB-14 in the Treatment of Mild Cognitive Impairment (MCI) or Mild and Moderate Dementia due to Alzheimer's Disease
(CTAD 2025)
- No abstract available
P2a data • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia
1 to 1
Of
1
Go to page
1